Acts as a sequence specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specific activity. Isoform 2 activates RIPK4 transcription. May be required in conjunction with TP73/p73 for initiation of p53/TP53 dependent apoptosis in response to genotoxic insults and the presence of activated oncogenes. Involved in Notch signaling by probably inducing JAG1 and JAG2. Plays a role in the regulation of epithelial morphogenesis. The ratio of DeltaN-type and TA*-type isoforms may govern the maintenance of epithelial stem cell compartments and regulate the initiation of epithelial stratification from the undifferentiated embryonal ectoderm. Required for limb formation from the apical ectodermal ridge. Activates transcription of the p21 promoter. Binds DNA as a homotetramer. Isoform composition of the tetramer may determine transactivation activity. Isoforms Alpha and Gamma interact with HIPK2. Interacts with SSRP1, leading to stimulate coactivator activity. Isoform 1 and isoform 2 interact with WWP1. Interacts with PDS5A. Isoform 5 (via activation domain) interacts with NOC2L. Widely expressed, notably in heart, kidney, placenta, prostate, skeletal muscle, testis and thymus, although the precise isoform varies according to tissue type. Progenitor cell layers of skin, breast, eye and prostate express high levels of DeltaN-type isoforms. Isoform 10 is predominantly expressed in skin squamous cell carcinomas, but not in normal skin tissues. Belongs to the p53 family. 12 isoforms of the human protein are produced by alternative promoter. Note: This description may include information from UniProtKB.
Molecular Function: chromatin binding; damaged DNA binding; DNA binding; double-stranded DNA binding; identical protein binding; metal ion binding; p53 binding; protein binding; sequence-specific DNA binding; transcription factor activity; WW domain binding
Biological Process: apoptosis; chromatin remodeling; cloacal septation; DNA damage response, signal transduction by p53 class mediator resulting in induction of apoptosis; DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; ectoderm and mesoderm interaction; embryonic limb morphogenesis; epidermal cell division; epithelial cell development; establishment of planar polarity; female genitalia morphogenesis; G1 DNA damage checkpoint; hair follicle morphogenesis; keratinocyte differentiation; keratinocyte proliferation; multicellular organismal aging; negative regulation of apoptosis; negative regulation of keratinocyte differentiation; negative regulation of transcription from RNA polymerase II promoter; negative regulation of transcription, DNA-dependent; neuron apoptosis; Notch signaling pathway; odontogenesis of dentine-containing teeth; polarized epithelial cell differentiation; positive regulation of mesenchymal cell proliferation; positive regulation of Notch signaling pathway; positive regulation of osteoblast differentiation; positive regulation of transcription from RNA polymerase II promoter; positive regulation of transcription, DNA-dependent; protein homotetramerization; proximal/distal pattern formation; regulation of apoptosis; regulation of caspase activity; regulation of epidermal cell division; regulation of neuron apoptosis; replicative cell aging; response to DNA damage stimulus; response to gamma radiation; response to X-ray; skeletal development; skin morphogenesis; smooth muscle development; spermatogenesis; sympathetic nervous system development; transcription from RNA polymerase II promoter; urinary bladder development
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.